SARS-CoV-2 IgG Antibody Levels After Inactivated Vaccine (CoronaVac) among Elderly

Günay CAN; İlker İNANÇ BALKAN; Neşe SALTOĞLU; Rıdvan KARAALİ; Bilgül METE; Beyhan BUDAK; Mehmet DEMİRCİ; Doğukan ÖZBEY; Bekir KOCAZEYBEK; Sevgi ERGİN; Harika Öykü DİNÇ

Dergiler / Infectious diseases and clinical microbiology (Online) / 2022 / Cilt: 4 - Sayı: 2

SARS-CoV-2 IgG Antibody Levels After Inactivated Vaccine (CoronaVac) among Elderly

Dergi: Infectious diseases and clinical microbiology (Online)
Sayı: 2022 · Cilt: 4 - Sayı: 2
Sayfa: 129–132
Yayın Tarihi: 2022-10-19
DOI: —

🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.

DergiPark Kaydı ↗

✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight

⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The median antibody titers after two vaccine doses were 561.3AU/mL and 43AU/mL, respectively(p

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:We aimed to describe the antibody response against SARS-CoV-2 after inactivated COVID-19 vaccine in elderly individuals.

📊

Temel Bulgular & Veri:SARS-CoV-2 IgG levels were measured in the blood samples of 126 volunteers over the age of 60.

💡

Sonuç & Katkı:The median antibody titers after two vaccine doses were 561.3AU/mL and 43AU/mL, respectively(p

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Abstract

We aimed to describe the antibody response against SARS-CoV-2 after inactivated COVID-19 vaccine in elderly individuals. SARS-CoV-2 IgG levels were measured in the blood samples of 126 volunteers over the age of 60. The antibody positivity rate was 42.8% after the first dose and 96.8% after the second dose of the vaccine. The median antibody titers after two vaccine doses were 561.3AU/mL and 43AU/mL, respectively(p

🔖

Bu Makaleye Atıf Yap

CAN, G., BALKAN, İ. İ., SALTOĞLU, N., KARAALİ, R., METE, B., BUDAK, B., DEMİRCİ, M., ÖZBEY, D., KOCAZEYBEK, B., ERGİN, S., DİNÇ, H. Ö. (2022). SARS-CoV-2 IgG Antibody Levels After Inactivated Vaccine (CoronaVac) among Elderly. Infectious diseases and clinical microbiology (Online), Cilt: 4 - Sayı: 2, 129–132. https://ajindex.com/articles/539056

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

1 Walker PGT, Whittaker C, Watson OJ, Baguelin M, Winskill P, Hamlet A, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries Science. 2020;369(6502):413-22. [CrossRef] 2 Flaxman S, Mishra S, Gandy A, Unwin TJH, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257- 61. [CrossRef] 3 Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-12. [CrossRef] 4 Establishment of the WHO international standard and reference panel for anti-SARS-CoV-2 antibody (WHO/BS/2020.2403) [Internet]. World Health Organization. (cited December 29, 2021). Available from: https://www.who.int/publications/m/ item/WHO-BS-2020.2403 5 SARS-CoV-2 Immunoassays [Internet]. Abbott. (cited December 29, 2021). Available from: https://www.corelaboratory.abbott/ int/en/offerings/segments/infectious-disease/sars-cov-2 6 Karamese M, Tutuncu EE. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. J Med Virol. 2022;94(1):173-7. [CrossRef] 7 Malavazos AE, Basilico S, Iacobellis G, Milani V, Cardani R, Boniardi F, et al. Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention. Obesity (Silver Spring). Feb 11, 2022. [Epub ahead of print]. [CrossRef] 8 Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. Jul 30, 2021. [Epub ahead of print]. [CrossRef] 9 Seyahi E, Bakhdiyarli G, Oztas M, Kuskucu MA, Tok Y, Sut N, et al. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. Rheumatol Int. 2021;41(8):1429-40. [CrossRef] 10 Bayram A, Demirbakan H, Günel-Karadeniz P, Erdoğan M, Koçer İ. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021;93(9):5560-7. [CrossRef]